Previous 10 | Next 10 |
SAN DIEGO , June 5, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, will participate in the upcoming 41 st Annual Goldman Sachs Global Healthcare Conference on Thursday, June 11, 2020 . Charles M. Baum , M.D., Ph.D.,...
SAN DIEGO , May 18, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that Joseph Leveque , M.D. has been named Chief Medical Officer effective May 18, 2020 . Isan Chen , M.D., will step down as Chief Medical...
SAN DIEGO , May 15, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced it will present preclinical data on the Company's pipeline of novel therapeutics in three presentations at the American Association for Cance...
Mirati Therapeutics (NASDAQ: MRTX ): Q1 GAAP EPS of -$2.02 misses by $0.34 . More news on: Mirati Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
SAN DIEGO , May 7, 2020 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results and a corporate update for the first quarter ended March 31, 2020 . "Despite the challenges many are facing related to the COVI...
Axcella Health (NASDAQ: AXLA ) initiated with Buy rating and $10 (115% upside) price target at BTIG Research. More news on: Axcella Health Inc., Viking Therapeutics, Inc., Y-mAbs Therapeutics, Inc., Healthcare stocks news, Stocks on the move, Read more ...
Shares of Verastem Oncology (NASDAQ: VSTM) , a biotechnology company developing novel cancer therapies, are sliding after a highly anticipated data drop failed to impress investors. Shares of the biotech stock were down 42.9% as of 12:12 p.m. EDT on Monday. This year, the American Associatio...
We are short shares of Mirati Therapeutics, a $4.6bn clinical-stage biopharmaceutical company whose lead drug candidate, MRTX-849, is a small-molecule KRAS inhibitor (KRASi). The KRAS protein plays a critical role in cell proliferation and differentiation, and mutations of the gene that encode...
Kerrisdale Capital reports that it is short Mirati Therapeutics ( MRTX -5.9% ) based on, what it considers, dim prospects for lead drug MRTX-849, citing early-stage data showing a low response rate and "incredibly short-lived" duration of response in lung cancer (NSCLC) patients. Ke...
ACADIA Pharmaceuticals (NASDAQ: ACAD ) initiated with Buy rating and $60 (33% upside) price target at Jefferies. More news on: ACADIA Pharmaceuticals Inc., eHealth, Inc., Lumos Pharma, Inc., Healthcare stocks news, Stocks on the move, , Read more ...
News, Short Squeeze, Breakout and More Instantly...
Mirati Therapeutics Inc. Company Name:
MRTX Stock Symbol:
NASDAQ Market:
Mirati Therapeutics Inc. Website:
First Solar Inc. (FSLR) is expected to report $3.19 for Q4 2023 VIZIO Holding Corp. Class A (VZIO) is expected to report $0.02 for Q4 2023 Henry Schein Inc. (HSIC) is expected to report $0.71 for Q4 2023 Republic Services Inc. (RSG) is expected to report $1.28 for Q4 2023 Forge Gl...
European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Jan. 10, 2024 /PRNewswire/ -- Mirati The...
2023-12-18 23:40:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...